ImpriMed, which builds AI-powered drug response prediction tech to help treat cancer in dogs and cats, raised a $23M Series A led by SoftBank Ventures Asia (Kate Park/TechCrunch)

Kate Park / TechCrunch:
ImpriMed, which builds AI-powered drug response prediction tech to help treat cancer in dogs and cats, raised a $23M Series A led by SoftBank Ventures Asia  —  ImpriMed, a California-based precision medicine startup, builds AI-powered dog cancer treatment technology that helps veterinarians identify …

Posted from: this blog via Microsoft Power Automate.

Do your Amazon shopping through this link.